adx-71149

ADX-71149 is a novel, first-in-class, potent, oral small molecule that acts as a selective positive allosteric modulator (PAM) of the metabotropic glutamate receptor 2 (mGlu2). It was developed by Addex Therapeutics in collaboration with Janssen Pharmaceuticals and Johnson & Johnson Innovative Medicine. The drug was investigated for several central nervous system disorders including epilepsy (specifically focal onset seizures), schizophrenia, and major depressive disorder with anxiety symptoms. Its mechanism involves enhancing the activity of mGlu2 receptors to regulate glutamate levels in the brain, aiming to normalize excessive glutamate release associated with seizure activity and psychiatric symptoms. While it showed synergistic efficacy with levetiracetam in preclinical epilepsy models and some efficacy in clinical trials for anxious depression, development has been discontinued for all indications after failing to meet endpoints in phase II studies[1][4][6][7].

Other names

JNJ-40411813JNJ40411813JNJ 40411813